Study of Safety and Efficacy Of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes And Hypertension (MK-8835-042)

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 194 participants.

Also called NCT01096667

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 194 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01096667
Other papers using this trial's data
  • Blood pressure-lowering effect of the sodium glucose co-transporter-2 inhibitor ertugliflozin, assessed via ambulatory blood pressure monitoring in patients with type 2 diabetes and hypertension Diabetes, obesity & metabolism, 2015-08 DOI, PubMed 25951755

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Not reported
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01096667. Randomized; double masking; primary purpose treatment. Start 2010-05-17 (actual); primary completion 2011-02-09 (actual). Results posted on 2017-12-13.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study of Safety and Efficacy Of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes And Hypertension (MK-8835-042)
Condition
Diabetes Mellitus, Type 2
Condition
Hypertension
Intervention (Drug)
Placebo to Ertuglilflozin 1 or 5 mg
Intervention (Drug)
Ertugliflozin 1 mg
Intervention (Drug)
Ertugliflozin 5 mg
Intervention (Drug)
Ertugliflozin 25 mg
Intervention (Drug)
HCTZ 12.5mg
Intervention (Drug)
Placebo to HCTZ
Intervention (Drug)
Placebo to ertuglilflozin 25 mg
Lead sponsor
Merck Sharp & Dohme LLC (class: industry)
Collaborator
Pfizer (class: industry)

Record details

Record id
cardio:ct-nct01096667
Content hash
454573487a61cf1174c7fe17b432990d9b8910f9ec04881a36a1b6afd5b370c0